CO6660464A2 - Anticuerpos que tienen inmunogenicidad reducida en un ser humano - Google Patents
Anticuerpos que tienen inmunogenicidad reducida en un ser humanoInfo
- Publication number
- CO6660464A2 CO6660464A2 CO12217151A CO12217151A CO6660464A2 CO 6660464 A2 CO6660464 A2 CO 6660464A2 CO 12217151 A CO12217151 A CO 12217151A CO 12217151 A CO12217151 A CO 12217151A CO 6660464 A2 CO6660464 A2 CO 6660464A2
- Authority
- CO
- Colombia
- Prior art keywords
- antibodies
- human
- reduced immunogenicity
- humans
- administered
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
Abstract
La descripción se refiere a anticuerpos diseñados por ingeniería que cuando se administran a un ser humano, exhiben un bajo nivel de inmunogenicidad en el ser humano. La descripción también se refiere a métodos para generar los anticuerpos. Los anticuerpos diseñados por ingeniería pueden derivarse de, por ejemplo, anticuerpos donadores no humanos (por ejemplo, de múrido) o de anticuerpos quiméricos o humanizados que, cuando se administran crónicamente a un ser humano, se pronostica que, o se espera que, produzcan una respuesta neutralizante de anti-anticuerpos en el ser humano.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33026110P | 2010-04-30 | 2010-04-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6660464A2 true CO6660464A2 (es) | 2013-04-30 |
Family
ID=44861933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO12217151A CO6660464A2 (es) | 2010-04-30 | 2012-11-29 | Anticuerpos que tienen inmunogenicidad reducida en un ser humano |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20140206849A1 (es) |
| EP (1) | EP2563812A4 (es) |
| JP (1) | JP2013531476A (es) |
| KR (1) | KR20130098161A (es) |
| CN (2) | CN103108885A (es) |
| BR (1) | BR112012027917A2 (es) |
| CA (1) | CA2798120A1 (es) |
| CO (1) | CO6660464A2 (es) |
| EA (1) | EA201291133A1 (es) |
| IL (1) | IL222691A0 (es) |
| MX (1) | MX2012012689A (es) |
| SG (1) | SG185107A1 (es) |
| WO (1) | WO2011137362A1 (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
| GB0426146D0 (en) | 2004-11-29 | 2004-12-29 | Bioxell Spa | Therapeutic peptides and method |
| JP5624276B2 (ja) | 2006-03-31 | 2014-11-12 | 中外製薬株式会社 | 抗体の血中動態を制御する方法 |
| EP3689912A1 (en) | 2007-09-26 | 2020-08-05 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
| TWI564021B (zh) | 2008-04-11 | 2017-01-01 | Chugai Pharmaceutical Co Ltd | Repeated binding of antigen to antigen binding molecules |
| SG185383A1 (en) | 2010-04-30 | 2012-12-28 | Alexion Pharma Inc | Anti-c5a antibodies and methods for using the antibodies |
| TW201241008A (en) * | 2010-10-01 | 2012-10-16 | Alexion Pharma Inc | Polypeptides that bind to human complement component C5 |
| MX365235B (es) | 2010-11-30 | 2019-05-28 | Chugai Pharmaceutical Co Ltd | Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno. |
| US9550830B2 (en) | 2012-02-15 | 2017-01-24 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
| PL2814844T3 (pl) | 2012-02-15 | 2017-12-29 | Novo Nordisk A/S | Przeciwciała wiążące i blokujące receptor aktywujący wykazujący ekspresję na komórkach szpikowych -1 (trem-1) |
| EP3456742A1 (en) | 2012-02-15 | 2019-03-20 | Novo Nordisk A/S | Antibodies that bind peptidoglycan recognition protein 1 |
| GB201220242D0 (en) * | 2012-11-09 | 2012-12-26 | Fusion Antibodies Ltd | Antibody |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| SG10201811017QA (en) * | 2013-06-26 | 2019-01-30 | Numab Innovation Ag | Novel antibody frameworks |
| NZ711451A (en) | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| PE20170192A1 (es) | 2014-07-17 | 2017-03-16 | Novo Nordisk As | Mutagenesis dirigida al sitio de anticuerpos receptor desencadenante expresado en las meloid tipo 1 (trem-1) para reducir la viscosidad |
| JP6948942B2 (ja) * | 2014-10-15 | 2021-10-13 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | タンパク質産物の等電性プロファイルをシフトさせる方法およびその使用 |
| TR201903267T4 (tr) | 2014-10-15 | 2019-03-21 | Alexion Pharma Inc | Büyük ölçekli eculizumab üretim hücre kültürünün replikasyon metotları. |
| KR102614189B1 (ko) | 2014-11-17 | 2023-12-18 | 리제너론 파아마슈티컬스, 인크. | Cd3xcd20 이특이적 항체를 이용한 종양의 치료 방법 |
| CN113045650A (zh) | 2014-12-19 | 2021-06-29 | 中外制药株式会社 | 抗-c5抗体及使用方法 |
| CA2981312C (en) | 2015-03-30 | 2023-09-26 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
| NL2014935B1 (en) * | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| CA3026050A1 (en) | 2016-08-05 | 2018-02-08 | Chugai Seiyaku Kabushiki Kaisha | Composition for prophylaxis or treatment of il-8 related diseases |
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| DK3658184T3 (da) | 2017-07-27 | 2023-11-27 | Alexion Pharma Inc | Højkoncentrerede anti-c5-antistofformuleringer |
| MA52190A (fr) | 2018-04-02 | 2021-02-17 | Bristol Myers Squibb Co | Anticorps anti-trem-1 et utilisations associées |
| CN112771077A (zh) | 2018-08-31 | 2021-05-07 | 瑞泽恩制药公司 | 针对cd3/c20双特异性抗体的减轻细胞因子释放综合征的给药策略 |
| CN114401988A (zh) * | 2019-07-09 | 2022-04-26 | 国家生物技术研究所公司 | 具有降低的免疫原性的抗体 |
| CN112210005B (zh) * | 2019-07-11 | 2024-03-26 | 京天成生物技术(北京)有限公司 | 低免疫原性低adcc/cdc功能的抗c5人源化单抗及其应用 |
| WO2022035888A2 (en) * | 2020-08-10 | 2022-02-17 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Sars-cov-2-neutralizing antibodies, biomarkers to predict protection from re-infection, and high efficiency antibody screening methods |
| JP2024502129A (ja) | 2021-01-12 | 2024-01-17 | エスジー メディカル インコーポレイテッド | Ｃｄ５５に対する新規抗体及びその用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6074642A (en) * | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| WO2003074679A2 (en) * | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
| WO2006117910A1 (ja) * | 2005-04-28 | 2006-11-09 | Mochida Pharmaceutical Co., Ltd. | 抗血小板膜糖蛋白質ⅵモノクローナル抗体 |
| KR20080098504A (ko) * | 2006-02-03 | 2008-11-10 | 메디뮨 엘엘씨 | 단백질 제제 |
| EP2219602A1 (en) * | 2007-11-15 | 2010-08-25 | Amgen, Inc | Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration |
-
2011
- 2011-04-29 CN CN2011800316723A patent/CN103108885A/zh active Pending
- 2011-04-29 BR BR112012027917A patent/BR112012027917A2/pt not_active IP Right Cessation
- 2011-04-29 KR KR1020127031101A patent/KR20130098161A/ko not_active Application Discontinuation
- 2011-04-29 WO PCT/US2011/034598 patent/WO2011137362A1/en active Application Filing
- 2011-04-29 EP EP11775642.9A patent/EP2563812A4/en not_active Withdrawn
- 2011-04-29 CN CN201410537722.0A patent/CN104402997A/zh active Pending
- 2011-04-29 EA EA201291133A patent/EA201291133A1/ru unknown
- 2011-04-29 MX MX2012012689A patent/MX2012012689A/es not_active Application Discontinuation
- 2011-04-29 CA CA2798120A patent/CA2798120A1/en not_active Abandoned
- 2011-04-29 JP JP2013508286A patent/JP2013531476A/ja not_active Withdrawn
- 2011-04-29 SG SG2012080404A patent/SG185107A1/en unknown
- 2011-04-29 US US13/695,250 patent/US20140206849A1/en not_active Abandoned
-
2012
- 2012-10-25 IL IL222691A patent/IL222691A0/en unknown
- 2012-11-29 CO CO12217151A patent/CO6660464A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112012027917A2 (pt) | 2017-11-28 |
| EP2563812A4 (en) | 2016-01-13 |
| JP2013531476A (ja) | 2013-08-08 |
| KR20130098161A (ko) | 2013-09-04 |
| EA201291133A1 (ru) | 2013-04-30 |
| WO2011137362A1 (en) | 2011-11-03 |
| US20140206849A1 (en) | 2014-07-24 |
| CA2798120A1 (en) | 2011-11-03 |
| CN103108885A (zh) | 2013-05-15 |
| CN104402997A (zh) | 2015-03-11 |
| MX2012012689A (es) | 2013-12-16 |
| EP2563812A1 (en) | 2013-03-06 |
| SG185107A1 (en) | 2012-12-28 |
| IL222691A0 (en) | 2012-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6660464A2 (es) | Anticuerpos que tienen inmunogenicidad reducida en un ser humano | |
| CO2017000506A2 (es) | Receptor quimérico de antígeno cll-1 | |
| CY1120707T1 (el) | Anti-cd28 εξανθρωπισμενα αντισωματα | |
| CO2017000510A2 (es) | Constructos de car | |
| UY35468A (es) | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 | |
| CO2017000507A2 (es) | Receptor quimérico de antígeno bcma | |
| CL2013001645A1 (es) | Secuencia de acido nucleico aislada que codifica un receptor de antigeno quimerico, el cual comprende un dominio de union a antigeno, un dominio transmembrana, una region de señalizacion coestimulatoria y un dominio de señalizacion cd3 zeta; dicho receptor; celula; vector; y su uso para tratar una enfermedad relacionada con la expresion elevada de un antigeno tumoral. | |
| AR080301A1 (es) | Anticuerpos e inmunoconjugados del receptor 1 de folato y sus usos | |
| BR112017022838A2 (pt) | receptores quiméricos de antígeno de antígenos de mieloma kappa e seus usos | |
| BR112016007805A2 (pt) | receptor de antígeno quimérico | |
| CR20140312A (es) | 4-fenil-piridinas sustiuidas para el tratamiento de enfermedades relacionadas con el receptor de nk1 | |
| BR112013032717A2 (pt) | coagonistas do receptor de glucagon/glp-1 | |
| NZ761537A (en) | Anti-human ox40l antibodies, uses & methods | |
| DOP2013000293A (es) | Composiciones líquidas de limpieza de sal | |
| CL2014002616A1 (es) | Anticuerpos anti-baff-anti-il-17 biespecíficos; composiciones que lo contienen y sus usos. | |
| MX2017011194A (es) | Anticuerpos, usos y métodos. | |
| DOP2013000195A (es) | Compuestos novedosos en base a ureas asimetricas, y usos medicos de los mismos | |
| CL2016002469A1 (es) | Sulfamidasa modificada y su producción | |
| CR20160083A (es) | Compuestos con actividad pesticida | |
| MX2019007252A (es) | Metodos y composiciones para vacunas del virus del dengue. | |
| BR112013013044A2 (pt) | modulação da imunogenicidade de antígeno pelo adição de epítopos reconhecidos por células nkt | |
| ITTO20120461A1 (it) | Agente per il controllo di ectoparassiti di animali. | |
| EA201591189A1 (ru) | Термостабильные водные композиции клоквинтосет-мексила | |
| WO2014194053A3 (en) | Carbohydrate compounds for nutritional and therapeutic use | |
| TR201009168A2 (tr) | Suda dağılan sefpodoksim proksetil formülasyonları. |